NCT04191252 is a clinical trial of A multi-gene panel testing in Epithelial Ovarian Cancer, sponsored by Lei Li.

Who is sponsoring NCT04191252?

NCT04191252 is sponsored by Lei Li.

What drugs are being tested in NCT04191252?

Interventions in NCT04191252: A multi-gene panel testing.

What condition does NCT04191252 study?

NCT04191252 studies Epithelial Ovarian Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation, Genomic Structural Variation, Total Mutation Burden, Microsatellite Instability, PD-1, PD-L1.

Is NCT04191252 still recruiting?

NCT04191252 is currently status unknown. Last updated 20 December 2019.

Last reviewed 2019-12-20 · How we verify

NCT04191252

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Mutation in Epithelial Ovarian Cancer

Status unknown Last updated 20 December 2019

What this trial tests

trial testing A multi-gene panel testing in Epithelial Ovarian Cancer in 500 participants. Status unknown.

Timeline

19 December 2019

Primary endpoint
1 January 2022

1 January 2023

Quick facts

Lead sponsor	Lei Li
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	19 December 2019
Primary completion	1 January 2022
Estimated completion	1 January 2023
Sites	1 location across China

Drugs / interventions tested

A multi-gene panel testing

Conditions studied

Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →
Nucleotide Variant — all drugs for Nucleotide Variant →
Copy Number Variation — all drugs for Copy Number Variation →
Insertion-deletion Variation — all drugs for Insertion-deletion Variation →

Sponsor

Lei Li — full company profile →

Who can join

18 and older, female only, with Epithelial Ovarian Cancer or Nucleotide Variant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Little is known about the characteristics of genetic mutation in a large multi-gene panel in epithelial ovarian cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes. The mutation characteristics are to be revealed in single nucleotide variants, copy number variations, insertion-deletion variations, and genomic structural variations. The total mutation burden (TMB) will be calculated. The status of microsatellite instability, expression of PD-1 and PD-L1 antibodies are also tested. These findings will be studies in association with the patients' prognosis and sensitivity to platinum-based chemotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Epithelial Ovarian Cancer

Currently open trials in the same condition.

NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
NCT07218809 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can · Phase 3 · recruiting
NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete · NA · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other Lei Li trials

Trials by the same sponsor.

NCT06558019 — Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence · not yet recruiting
NCT06557954 — Cervical Cytology DNA Methylation for Cervical Cancer Screening · not yet recruiting
NCT05801263 — ctDNA Methylation for Epithelial Ovarian Cancer · unknown
NCT05801276 — ctDNA Methylation for Detecting Ovarian Cancer · unknown
NCT06490380 — HRD Status Reference Standard Based on WGS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04191252 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lei Li
Last refreshed: 20 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04191252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing